Harmony Biosciences Holdings financials
$39.29−1.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $261.3M | $215.4M | $243.8M | $239.5M | $200.5M | $184.7M | $201.3M | $186.0M | $172.8M | $154.6M | $168.4M | $160.3M |
| Gross profit | $198.1M | $170.9M | $175.2M | $179.8M | $162.3M | $152.7M | $146.9M | $143.3M | $140.7M | $127.1M | $125.3M | $128.0M |
| Gross margin | 75.8% | 79.3% | 71.9% | 75.1% | 81.0% | 82.7% | 73.0% | 77.0% | 81.4% | 82.2% | 74.4% | 79.8% |
| Operating income | $89.3M | $37.3M | $38.6M | $65.5M | $48.2M | $56.2M | $55.7M | $61.7M | $21.4M | $52.0M | $40.2M | $64.5M |
| Net income | $75.4M | $32.5M | $22.5M | $50.9M | $39.8M | $45.6M | $49.5M | $46.1M | $11.6M | $38.3M | $26.6M | $38.5M |
| Net margin | 28.9% | 15.1% | 9.2% | 21.2% | 19.8% | 24.7% | 24.6% | 24.8% | 6.7% | 24.8% | 15.8% | 24.0% |
| Diluted EPS | $1.28 | $0.55 | $0.38 | $0.87 | $0.68 | $0.78 | $0.85 | $0.79 | $0.20 | $0.67 | $0.45 | $0.63 |
| EBITDA | $83.4M | $43.3M | $46.0M | $71.5M | $42.2M | $62.2M | $61.7M | $67.7M | $27.4M | $58.2M | $46.3M | $70.6M |
| Operating cash flow | $92.4M | $27.8M | $126.2M | $108.7M | $79.3M | $34.0M | $75.6M | $70.5M | $42.6M | $31.1M | $76.7M | $63.1M |
| Free cash flow | $92.4M | $27.8M | $126.0M | $108.7M | $79.3M | $33.9M | $75.0M | $70.5M | $42.0M | $31.1M | $76.6M | $63.1M |
| Diluted shares | 58.8M | 58.8M | 58.5M | 58.7M | 58.4M | 58.5M | 58.2M | 58.1M | 57.5M | 57.6M | 58.8M | 60.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $549.8M | $589.4M | $752.5M | $647.0M | $546.0M | $489.0M |
| Short-term investments | $118.0M | $51.5M | $22.8M | $25.6M | $19.2M | $18.0M |
| Total debt | $154.0M | $158.8M | $163.7M | $168.5M | $172.1M | $175.7M |
| Total assets | $1.37B | $1.27B | $1.27B | $1.21B | $1.11B | $1.06B |
| Total liabilities | $373.8M | $361.5M | $401.4M | $373.1M | $334.9M | $335.0M |
| Shareholders' equity | $999.2M | $910.3M | $870.2M | $835.1M | $773.1M | $720.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology